The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityRecent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosisVoriconazole pharmacokinetics in liver transplant recipients.Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, andHydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian populationPharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML.Genotype and allele frequency of CYP2C19*17 in a healthy Iranian populationTherapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentPharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy.Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Regulatory polymorphisms in CYP2C19 affecting hepatic expressionFunctional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.Voriconazole therapeutic drug monitoring: focus on safety.Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and anti-inflammatory drugs.Pharmacogenomics of the triazole antifungal agent voriconazole.Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.Voriconazole serum concentrations in obese and overweight immunocompromised patients: a retrospective review.Pharmacokinetic behavior presents drug therapy challenges.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.A challenging case of invasive pulmonary aspergillosis after near-drowning: a case report and literature review.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis.PharmGKB summary: voriconazole pathway, pharmacokinetics.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Voriconazole metabolism is influenced by severe inflammation: a prospective study.Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.Analysis of imidazoles and triazoles in biological samples after MicroExtraction by packed sorbent.Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
P2860
Q27009221-C0E1A705-F2E7-4FFA-B710-F761ADB03C09Q28080256-E52F60DC-CD82-4D47-99B9-6E7086453A10Q28675835-E9CD1BE1-2769-4F0D-9F65-ABCDE65FF5D1Q33613685-06A5A300-A7A2-429B-BC07-BE9629407D75Q33684379-C45E2630-E88F-430F-B07A-80162C034FDFQ33692784-AC32010B-FCE4-4918-B976-5344922B9D44Q33849298-AB6AE4AE-88E4-4DC1-B85C-87E359B5153BQ34138276-8DAAA150-1EFA-4AE2-885A-4D17110E6412Q34309603-0B5CAA81-E206-4225-89A6-9C32AE9F8EA4Q34706677-956F9C29-D1E4-44B1-B651-CC5CC331B7A2Q35364006-6D65C183-1D4A-4B72-98B3-66E4FE71175DQ35617669-14527528-1149-422B-8D2C-0A1F5580730BQ35936943-878A18B4-B3B4-4653-B9F7-6421B2D8A857Q36185299-5E6E883E-9FDC-4DB6-A9AC-8DF51EF750B4Q36469405-FE08E80A-20D3-4D4B-A7D6-A46E1D09D50CQ36608562-8E833C65-3A11-4BA3-AB84-33C0D673C155Q36643041-77C4D309-8442-4672-BCAF-CE683562A22CQ36730105-71EAB457-452F-4A98-A2F7-BAB1B89CFEB5Q37086418-06699727-F4AC-46D1-A9B7-3972380A2A79Q37127419-5EE42D26-F71C-43D0-82FA-58A19EEBF693Q37199426-82D57EE8-7A22-4C00-AB64-14CA2D3870DAQ37658869-F5AECABD-CEA6-4F69-8D1E-72A282D322B7Q37806065-1F616ACA-A581-44D6-B13E-F68CFC5C888FQ37892531-B46A75CF-DD4C-4981-A064-1054810374AEQ37892536-A7935661-3062-4397-8AD7-19DEB8499E1CQ37904672-4978F688-4787-453E-A322-C2D059AACAE6Q37945308-A282E2A9-B729-4905-9321-C200A70844DCQ38073201-E6676DF2-BA56-4B8B-98F7-02893650162BQ38155930-16D9A342-FCED-4213-92D4-CD1689C9F605Q38284468-A6DB4649-C526-481E-BDF3-CBC30BDA899BQ38526795-43A39708-B839-495E-9BC3-2F986F7A1A58Q38590801-E05F1ECA-DA2B-4F7D-A37C-431F8F3CB690Q38775809-4B214A00-BE2F-44C0-9C53-B619B78E1FB6Q38889189-0B0C66EA-5101-445B-910E-80AEEAB74E47Q38918175-89F7B4C7-CB69-4136-8C3C-8B2ED6C49649Q39196770-329A1535-9CCE-49A4-8E10-66C5DA6DAF93Q39416464-6397D61A-CB19-4C87-95C8-E77AFEC075C2Q39797076-78FEB231-554D-4CC9-ACEF-6A19E61E4136Q40106868-81913477-E83E-41E9-BF21-B994E16D2F57Q40290020-138DE8F0-6C7D-4161-B8DD-0F9AEB86EC51
P2860
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
The CYP2C19 ultra-rapid metabo ...... le in healthy male volunteers.
@en
The CYP2C19 ultra-rapid metabo ...... le in healthy male volunteers.
@nl
type
label
The CYP2C19 ultra-rapid metabo ...... le in healthy male volunteers.
@en
The CYP2C19 ultra-rapid metabo ...... le in healthy male volunteers.
@nl
prefLabel
The CYP2C19 ultra-rapid metabo ...... le in healthy male volunteers.
@en
The CYP2C19 ultra-rapid metabo ...... le in healthy male volunteers.
@nl
P2093
P1476
The CYP2C19 ultra-rapid metabo ...... le in healthy male volunteers.
@en
P2093
Dong-Li Hu
He-Ping Lei
Hong-Hao Zhou
Zhi-Rong Tan
P2888
P304
P356
10.1007/S00228-008-0574-7
P577
2008-11-04T00:00:00Z